Re: ALNY trades for about 150X projected 2016 revs per share; ISIS trades for about 20X projected 2016 revs per share.
A lot of good points. The Isis bashers on this board will quickly point to the street losing their confidence a number of times pointing to the lack of commercial success for the first 3 FDA approved drugs: Vitrene, Alicaforsen and Kynamro (which by the way has still not been approved for use by the EU, USA and a few other countries so far.) For me I don't get the high valuation for Alny at all. The street is dissing Isis at their own potential loss of making money with Isis. This too shall change hopefully sooner than later-but the facts and journey have already been carved in stone, so get on board now to maximize your investment.